CIAM
ANIX icon

Caitong International Asset Management’s Anixa Biosciences ANIX Stock Holding History

Caitong International Asset Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39 Buy
14
+13
+1,300% +$36 ﹤0.01% 2392
2026
Q1 		$3 Buy
+1
New +$3 ﹤0.01% 2364

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Caitong International Asset Management's ANIX Position: Q2 2026 in Review

Caitong International Asset Management increased its Anixa Biosciences (ANIX) stake by 1,300% in Q2 2026, buying an estimated $36 and bringing the position to 14 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Caitong International Asset Management first reported a position in ANIX in Q1 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Caitong International Asset Management held 14 shares of Anixa Biosciences worth $39 as of Q2 2026.
  • Caitong International Asset Management bought 13 Anixa Biosciences shares in Q2 2026, an estimated $36.
  • Anixa Biosciences made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2392 holding.
  • Caitong International Asset Management first reported a position in Anixa Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.